NCT06971900已完成2 期
A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Plasma PPIX level
研究概览
简要总结
A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Major Inclusion Criteria:
- •BMI ≥18.0 and ≤40.0 kg/m2 and weight ≥50 kg on Day -
- •Nonsmoker or willing to refrain from the use of nicotine or tobacco-containing products for at least 30 days prior to the first dose of study drug based on participant self-reporting and agrees to refrain from the use of these products throughout the study.
- •Known diagnosis of EPP.
- •History of consistent, non-painful prodrome prior to phototoxic attacks.
- •Experiences prodrome within 40 minutes of uncovered sunlight exposure.
- •Willing and able to follow protocol-specified contraception guidance.
- •Able to read and understand English and is willing and able to provide document informed consent to participate in the study at the time of the Remote Screening Visit and at the In-Clinic Screening Visit.
- •Able to understand the study procedures as described in the ICF and is willing and able to comply with the study requirements.
排除标准
- •Is mentally or legally incapacitated or has significant emotional problems identified or observed during the screening period or expected during the conduct of the study that could lead to difficulty complying with study procedures or interfere with the safe completion of the study.
- •History or presence of any illness or clinically significant medical or psychiatric condition or disease that, in the opinion of the PI or designee, might confound the results of the study or pose an additional risk to the participant by their participation in the study.
- •Current alcohol or drug use disorder, as defined by the DSM-V-TR.
- •History of gastrointestinal condition, including surgeries, which may affect absorption after oral administration.
- •History of cancer, with the exception of cutaneous non-melanoma skin cancer (basal or squamous cell carcinoma).
- •Received another investigational medicine within 5 half-lives, if the half-life is known, or within 28 days, if the half-life is unknown, prior to Day
- •Surgical procedure planned within 28 days prior to Day
- •Donation of blood or significant blood loss within 60 days prior to Day
- •Plasma donation within 7 days prior to Day
- •Unable to refrain from or anticipates the use of any of the following beginning 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study drug and throughout the study:
- •Substrates of BCRP or MATE1/2-K
- •CYP3A4 substrates that cannot be separated by at least 2 hours from PORT-77 dosing
- •Moderate or strong P-gp inhibitors or inducers
- •Moderate or strong CYP3A4 inhibitors or inducers
- •Herbal supplements or food products containing grapefruit juice, star fruit, or Seville oranges
- •Illicit substances (eg, opiates, amphetamines, cocaine, cannabinoids [including prescription medical cannabis]).
- •With the following exceptions, is unable to refrain from or anticipates the use of any nonprescription medications and herbal/nutritional supplements beginning 14 days prior to the first dose of study drug and throughout the study:
- •A daily multivitamin
- •Single use of acetaminophen, aspirin, or ibuprofen at a dose equal to or lower than that recommended on the package
- •Estimated glomerular filtration rate <60 mL/min/1.73 m2 using the CKD-EPI equation on Day -
- •In the absence of known mild hepatic impairment, alanine aminotransferase or aspartate aminotransferase ≥3 × ULN, or total bilirubin ≥2 × ULN (unless documented Gilbert syndrome) on Day -
- •Moderate (Class B) or severe (Class C) hepatic impairment as measured by the Child-Pugh score reported historically or calculated on Day -
- •Female participant with a positive pregnancy test on Day -1 or who is breastfeeding.
- •Positive urine drug or alcohol results on Day -
- •Positive results for HIV, HBsAg, or HCV antibody and HCV RNA on Day -
- •Note, for participants successfully treated for HCV, positive antibody test with external laboratory evidence of negative RNA test is not exclusionary.
研究组 & 干预措施
PORT-77
Experimental
Active
干预措施: PORT-77 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Plasma PPIX level
时间窗: 9 Days
Change over the course of the study in plasma PPIX concentrations
次要结局
- Evaluate safety and tolerability of 2 different dose regimens of PORT-77(9 Days)
- Cmax(Predose and 1, 2, 3, 4, 6, 8, 12 hours post dose)
- AUC0-last(Predose and 1, 2, 3, 4, 6, 8, 12 hours post dose)
- Tmax(Predose and 1, 2, 3, 4, 6, 8, 12 hours post dose)
- Maximum Observed Plasma Concentration (Cmax)(Day 1 through Day 9)
- Safety and tolerability(9 Days)
- Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last)(Day 1 through Day 9)
- Area Under the Plasma Concentration-Time Curve Over the 12-Hour Dosing Interval at Steady State (AUC0-12)(Up to Day 8)
- Area Under the Plasma Concentration-Time Curve Over the 24-Hour Dosing Interval at Steady State (AUC0-24)(Up to Day 8)
- Trough Plasma Concentration (Ctrough)(Up to Day 8)
- Time to Maximum Observed Plasma Concentration (Tmax)(Day 1 through Day 9)
- Time of Last Quantifiable Plasma Concentration (Tlast)(Day 1 through Day 9)
- Terminal Elimination Half-Life (t½)(Day 1 through Day 9)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological ImpairmentMethylmalonic Aciduria and Homocystinuria,Cblc TypeRetinopathyGenetic DiseaseNCT01793090Bambino Gesù Hospital and Research Institute30
终止
2 期
An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02366637Pfizer13
终止
1 期
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01028911Pfizer9
已完成
2 期
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not HospitalizedSARS-CoV-2 InfectionNCT05799495Pfizer240
已完成
2 期
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing CholangitisPruritusNCT05525520Escient Pharmaceuticals, Inc62